0.85 USD
▼-0.05-5.53%
盘后 1.05 0.00%
2026-11-20
市值
$47.99M
市盈率
—
EPS
-0.58
股息率
—
52 周区间
0.84 – 3.96
成交量
70.62K
Beta
0.72
目标价
—
52W 低 0.8452W 高 3.96
价格走势
公司简介
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The ...